Collegium Pharma (COLL) Tops Q3 EPS by 4c

Collegium Pharma (NASDAQ: COLL) reported Q3 EPS of $1.61, $0.04 better than the analyst estimate of $1.57. Revenue for the quarter came in at $159.3 million versus the consensus estimate of $156.88 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.

You May Also Be Interested In

• KeyBanc sees stronger US self storage pricing trends in July
• RadNet (RDNT) Tops Q2 EPS by 9c; offers guidance
• Cipher Mining (CIFR) Reiterated at Market Outperform by Citizens on AI Infra Pipeline